Archive
All news, publications, and updates from Seek Labs.
Jared Bauer Named Salt Lake City Titan 100 2026 Honoree April 20, 2026 Jared Bauer, co-founder and CEO of Seek Labs, has been named a 2026 Salt Lake City Titan 100 honoree. The Titan 100 program recognizes the region’s top 100 CEOs and C-level executives, selected for their exceptional leadership, vision, and impact across industries.…
Seek Labs Joins BioMaP-Consortium to Support U.S. Biomanufacturing Preparedness Efforts As a member of the BioMaP-Consortium, Seek Labs gains access to a collaborative network advancing next-generation biomanufacturing and healthcare innovation. March 19, 2026 Seek Labs today announced that it has joined the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), a national public-private partnership focused on strengthening the…
For Continuously Evolving Threats like Avian Influenza, We Must Design Durable Anti-Viral Therapeutics Highly pathogenic avian influenza (HPAI) illustrates a clear and urgent application for Seek Labs’ platform based programmable therapeutic. By Dr. Douglas Gladue | March 11, 2026 Highly pathogenic avian influenza (HPAI) is a persistent and economically disruptive disease threat. It has been…
Seek Labs Awarded $2 Million Federal Grant for a Novel CRISPR-Based, Mutation-Resistant Therapeutic to Combat Avian Flu in Partnership with Canadian Food Inspection Agency USDA grant is part of a broader federal push to find innovative solutions to fight the highly infectious avian flu (HPAI), which continues to spread globally and impact egg and poultry…
Next Generation CRISPR: How Seek Labs’ Programmable Therapeutics Are Expanding the Promise of CRISPR-Powered Innovation At Seek Labs, every day is World CRISPR Day. Our work in programmable therapeutics builds upon the same principles that make CRISPR so revolutionary: precision, adaptability, and speed. As we reflect on this transformative technology, we’re not just looking at…
Seek Labs Expands Global Disease Atlas with Mapping of Hemorrhagic Fever Viruses through BioSeeker™ October 21, 2025 Salt Lake City, UT (Business Wire)–Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery programmable therapeutics, and point-of-care diagnostics, today announced an expansion of its Global Disease Atlas™ to include multiple hemorrhagic fever viruses.…
Seek Labs Advances Development of Pan-Orthopoxvirus Therapeutic with BioSeeker™ and PTAP™ October 7, 2025 BioSeeker mapped more than 10,000 isolates and identified targetable regions that provide 100% strain coverage across the viral family. Early in vitro testing of the BioSeeker-developed therapeutic construct achieved up to 90% viral knockdown in a vaccinia virus model, laying the…
Seek Labs Vice President of Research, Dr. Anindita Roy, Honored with 2025 Women Tech Council Rising Star Award October 6, 2025 Seek Labs is proud to announce our Vice President of Research, Dr. Anindita “Annie” Roy, has been selected as the Rising Star Award recipient by the Women Tech Council as part of the 2025…
Seek Labs Selected as Participant of ARPA-H Investor Catalyst Hub Spoke Network and Rapid Response Partnership Vehicle (RRPV) September 24, 2025 Salt Lake City, UT (Business Wire) – Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, announced today that it has joined two federally supported…
Stay connected
Stay connected to company milestones, scientific insights, and the work unfolding across BioSeeker, SAT, and Seek Diagnostics.